Medipharm Labs ‘welcomes’ executive order on cannabis reclassification

MediPharm Labs (MEDIF) welcomes U.S. President Donald Trump’s executive order to expedite the reclassification of cannabis under the U.S. Controlled Substances Act from Schedule I to Schedule III. “This reclassification order is a historic milestone that validates MediPharm’s pharmaceutical approach and one that we anticipate will strengthen our ability to expand U.S. clinical trial partnerships,” said David Pidduck, CEO. “This change could facilitate significant growth in clinical research, and MediPharm is uniquely prepared to support clinical trial partners and patients. We have already shipped product for U.S. trials, a capability that others may take years to achieve.”